NGLFINE2024-10-012024-12-31 NGLFINE2024-10-012024-12-31 NGLFINE2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member NGLFINE2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member NGLFINE2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524774 NGLFINE NOTLISTED NGL Fine-Chem Limited Equity 2024-04-01 2025-03-31 2025-02-07 2025-01-30 INR Lakhs Third quarter 18:00:00 19:00:00 2025-02-07 2025-02-07 Not applicable Single segment PHARMACEUTICALS 2024-10-01 2024-12-31 Unaudited Consolidated 890988000.00 -1319000.00 889669000.00 479336000.00 0.00 -44047000.00 146628000.00 6005000.00 30990000.00 258104000.00 877016000.00 12653000.00 0.00 12653000.00 11262000.00 -11375000.00 -113000.00 0.00 12766000.00 0.00 0.00 0.00 0.00 12766000.00 622000.00 13388000.00 0.00 0.00 0.00 0.00 30890000.00 5 2.07 2.07 0.00 0.00 2.07 2.07 Notes: 1. The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 7th February, 2025. These results are subjected to Limited Review by the Statutory Auditors of the Company. 2. The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 Operating Segment notified pursuant to Companies (Indian Accounting Standards) Rules 2015 3. The consolidated results are for NGL Fine-Chem Limited together with its 100% subsidiary Marcotech Polychem Private Limited 4. Previous period figures have been regrouped/rearranged wherever necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 2733362000.00 105907000.00 2839269000.00 1350984000.00 0.00 -2220000.00 412988000.00 13605000.00 91306000.00 708788000.00 2575451000.00 263818000.00 0.00 263818000.00 61262000.00 -527000.00 60735000.00 0.00 203083000.00 0.00 0.00 0.00 0.00 203083000.00 -2290000.00 200793000.00 0.00 0.00 0.00 0.00 30890000.00 5 32.87 32.87 0.00 0.00 32.87 32.87 Other Expenses 258104000.00 Other Expenses 708788000.00 -832000.00 3061000.00 210000.00 -771000.00